Idebenone: When an antioxidant is not an antioxidant
Idebenone is a well described drug that was initially developed against dementia. The current literature widely portrays this molecule as a potent antioxidant and CoQ10 analogue.
Nuri Güven +2 more
exaly +6 more sources
Idebenone: Clinical Potential Beyond Neurological Diseases [PDF]
Bin Yi,1– 4,* Jun Zeng,1– 4,* Jiashuo Li,1– 4,* Kunfeng Liu,1– 4 Xiaocheng Zhu,4,5 Xiang Chen,4,5 Yang Gao1– 4 1Department of Thoracic Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, People’s Republic of ...
Yi B +6 more
doaj +4 more sources
Idebenone Mitigates Traumatic-Brain-Injury-Triggered Gene Expression Changes to Ephrin-A and Dopamine Signaling Pathways While Increasing Microglial Genes [PDF]
Traumatic brain injury (TBI) leads to persistent pro-inflammatory microglial activation implicated in neurodegeneration. Idebenone, a coenzyme Q10 analogue that interacts with both mitochondria and the tyrosine kinase adaptor SHC1, inhibits aspects of ...
Hyehyun Hwang +9 more
doaj +2 more sources
Background: Idebenone is an antioxidant and a coenzyme Q10 analog that has been used to treat neurodegeneration disease. Some studies show idebenone exerts anti-inflammatory effects.
Zhihua Liu, Na Wu
exaly +3 more sources
Comparative Antioxidant Protection of Cochlear Hair Cells from Ototoxins [PDF]
Many forms of damage to cochlear sensory cells involve reactive oxygen species (ROS). We previously screened 81 antioxidants in vitro for the ability to reduce cochlear hair cell (HC) damage by the ototoxic aminoglycoside gentamicin. Only 13 antioxidants
Allen F. Ryan +3 more
doaj +2 more sources
Idebenone increases mitochondrial complex I activity in fibroblasts from LHON patients while producing contradictory effects on respiration [PDF]
Background Leber's hereditary optic neuropathy (LHON) is caused by mutations in the complex I subunits of the respiratory chain. Although patients have been treated with idebenone since 1992, the efficacy of the drug is still a matter of debate.
Angebault Claire +13 more
doaj +7 more sources
Idebenone vs. rAAV2-ND4 gene therapy in the treatment of Leber’s hereditary optic neuropathy: An indirect comparison meta-analysis [PDF]
To compare the outcomes between idebenone oral therapy and rAAV2-ND4 intravitreal injection in the treatment of Leber’s hereditary optic neuropathy. A systematic literature review was performed of publications from 1990 to 2023 in PubMed, Ovid MEDLINE ...
Amr K Hassan, Hashem Abu Serhan
doaj +2 more sources
IT TAKES TWO TO TANGO: potential novel therapies for autosomal dominant optic atrophy [PDF]
Autosomal dominant optic atrophy (ADOA) is among the most prevalent inherited optic neuropathies with hallmark symptoms of bilateral, painless, progressive, and typically permanent vision loss over time.
Ritu Sampige +14 more
doaj +2 more sources
Idebenone is a ubiquinone short-chain synthetic analog with antioxidant properties, which is believed to restore mitochondrial ATP synthesis. As such, idebenone is investigated in numerous clinical trials for diseases of mitochondrial aetiology and it is
Maria Elisabetta Clementi +2 more
exaly +3 more sources
Idebenone alleviates doxorubicin-induced cardiotoxicity by stabilizing FSP1 to inhibit ferroptosis
Doxorubicin (DOX)-mediated cardiotoxicity can exacerbate mortality in oncology patients, but related pharmacotherapeutic measures are relatively limited. Ferroptosis was recently identified as a major mechanism of DOX-induced cardiotoxicity. Idebenone, a
Hongliang Qiu +12 more
exaly +3 more sources

